Elon Musk’s announcement that 2026 will be Neuralink’s “mass production year” has generated considerable attention in the enhancement community. The company reports over twenty implanted subjects worldwide, FDA breakthrough device designation, and expansion into UK and Canadian clinical trials. Their new Austin facility is preparing for what Musk describes as “high-volume production” with “almost entirely automated surgical procedures.”
These are significant achievements. They also raise questions worth examining.
The Language of Scale
“Mass production” is a term borrowed from manufacturing — from automobiles and consumer electronics, from industries where uniformity is a virtue and variation is a defect. It implies interchangeable parts, standardized processes, predictable outputs.
Human brains are none of these things.
Every neural architecture is unique. The precise location of language centers, motor regions, and cognitive processing networks varies between individuals by millimeters that matter enormously when you’re threading electrodes through living tissue. What works optimally for Subject 14 may produce suboptimal results — or adverse events — in Subject 15.
At Unzyme Laboratories, we’ve learned this through experience. Our SynthCortex integration procedures require pre-operative neural mapping that takes, on average, eleven hours per patient. This cannot be automated without accepting compromises we’re unwilling to make.
Automation and Oversight
We don’t doubt that Neuralink has developed sophisticated surgical robotics. The question isn’t whether robots can place electrodes — clearly they can. The question is whether automated systems can respond appropriately to the unexpected.
What happens when intraoperative imaging reveals an anatomical variation not present in the patient’s pre-surgical scans? What happens when real-time neural feedback suggests the target region is more distributed than modeling predicted? What happens when something goes wrong?
Automation excels at the expected. Human expertise is irreplaceable for everything else.
Different Philosophies
We should be clear: Unzyme Laboratories and Neuralink are pursuing different visions. Neuralink’s stated goal is broad accessibility — bringing neural interfaces to millions of people who could benefit from restored motor function or communication capability. This is a worthy goal that we support.
Our focus is different. We optimize for depth of integration rather than breadth of deployment. Our volunteer cohort is smaller. Our procedures are longer. Our enhancements go further.
Neither approach is wrong. They serve different populations with different needs.
A Caution
What concerns us is not competition — we welcome it — but the possibility that “mass production” framing may create unrealistic expectations. Neural interfaces are not smartphones. They cannot be upgraded annually. They cannot be factory reset when they malfunction. They become, quite literally, part of who you are.
We urge potential recipients of any neural interface technology, whether from Neuralink or any other provider, to ask difficult questions: What is the revision rate? What happens if the device fails? What long-term monitoring is included? What data is collected, and who owns it?
The answers matter more than the marketing.
Our Commitment
Unzyme Laboratories will continue our approach: careful selection, exhaustive preparation, individualized integration, and lifetime monitoring for every volunteer who trusts us with their enhancement. We produce fewer enhanced individuals than Neuralink plans to produce. We believe each of them receives something that mass production cannot provide.
Time will tell which approach better serves humanity’s enhancement journey.
Dr. Elena Voss is Chief Science Officer at Unzyme Laboratories.